Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP
Adverum Biotechnologies (NASDAQ:ADVM) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, down previously from $30.00.
Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors [Yahoo! Finance]